ＡＤＲバイオメディカルホールディングス rose for a fourth straight day. Its subsidiary, ＡＤＲセラピューティクス, announced that it would begin a clinical trial of a treatment using adipose-derived regenerative cells for critical limb ischemia.
The share price of ＡＤＲバイオメディカルホールディングス has risen for 4 consecutive days. On the 28th, the company announced that its subsidiary, ＡＤＲセラピューティクス, had begun a clinical trial of a treatment using ADRCs for critical limb ischemia. The company explained that the clinical trial falls within a phase equivalent to Phase 3 as a confirmatory study.
With the aim of commercializing the treatment and obtaining insurance coverage, the company had been validating its efficacy under a joint research agreement with Nagoya University, leading to the decision to begin the clinical trial. The clinical trial protocol was said to have been nearly finalized following a formal consultation with the Pharmaceuticals and Medical Devices Agency (PMDA).
The name Saito Takumi (齋藤 匠) was given as the presenter. Progress and the disclosure of the latest information will be closely watched as preparations continue for the formal implementation of the clinical trial.